Based on brands, the market is segmented into Januvia, Onglyza/Kombiglyze, Tradjenta, Nesina, Galvus, and other brands.
The Tradjenta market will surpass Merck’s Januvia during the forecast period. The global Tradjenta market is expected to register a CAGR of 5.7 %, during the forecast period, 2019-2024, and is expected to surpass the Januvia market, which held the maximum market share in 2018. The Tradjenta market includes its combination Jentadueto and Jentadueto XR, a combination of linagliptin (Tradjenta) and metformin hydrochloride, for use in the treatment of type 2 diabetes. The type-2 diabetes drug, Tradjenta (linagliptin) was not launched in Germany, because of a decision by the county’s reimbursement authority, which concluded that it doesn’t provide any additional benefits, compared to the medicines already on the market.
North America holds the highest market share. North America holds 38% of the market share in the global DPP-4 market, followed by the Asia Pacific. Increasing diabetes prevalence in established and emerging countries is expected to drive the market. This increase, over the years, is due to the overall effect of individual-level factors, like an increasing median age of the population and health factors, including obesity and inactivity levels among people.
Lowering birth rates, along with increasing life expectancy in countries like Japan, Italy, Germany, and France, which have a high percentage of the geriatric population, are expected to drive the growth of the market.
North America and Europe dominates the global market for DPP IV inhibitors due to high prevalence rate and rising awareness among people about the DPP IV inhibitors. Latin America is considered as a fastest growing market due to increasing obese population.
Top Major Players
Merck held the highest market share in the DPP-4 market in 2018 and is expected to maintain its position till 2022. After that, it may witness a decline in market share, due to the expected launch of a generic version of Sitagliptin in 2022. The major players are Merck, AstraZeneca and Eli Lilly.